CPRX News and Press, Catalyst Pharmaceuticals Inc. From 05/10/23

2023-05-10 16:38:30 ET Catalyst Pharmaceuticals press release ( NASDAQ: CPRX ): Q1 Non-GAAP EPS of $0.41 beats by $0.10 . Revenue of $85.4M (+98.2% Y/Y) beats by $3.78M . Cash and equivalents were $148.2 Million as of March 31, 2023. Affirms Full Year Tot...

Reports Record Total Revenues of $85.4 Million for Q1 2023 Delivers Revenue Growth of 98%, a Record Increase YoY GAAP EPS Diluted of $0.26 Per Share; a 117% Increase YoY Non-GAAP EPS Diluted of $0.41 Per Share, an Increase of 128% YoY Affirms F...

Concluded Positive FDA Type-C Meeting in Early May 2023 Company On Track to Submit an sNDA Early in the Third Quarter of 2023 CORAL GABLES, Fla., May 09, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical ...

CORAL GABLES, Fla., May 01, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases today announce...

CORAL GABLES, Fla., April 24, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today...

CORAL GABLES, Fla., April 20, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare disea...

2023-04-19 07:51:25 ET Summary The extent to which FIRDAPSE in the treatment of LEMS can support ongoing growth is a big question mark for Catalyst shareholders. The FYCOMPA acquisition comes with more big question marks. Although enjoying comfortable liquidity, Catalyst will ...

2023-04-18 12:00:51 ET Summary Catalyst Pharmaceuticals, Inc. filed a lawsuit against Teva Pharmaceutical Industries Limited's ANDA. At the heart of the situation is a patent that should never have been granted. While courts have not addressed this, instead focusing on orphan ...

2023-04-17 15:42:50 ET Summary Catalyst Pharmaceuticals, Inc. appears to be set up nicely for earnings and revenue growth with a possible expansion of its valuation ratios. Downside appears to be limited, as Catalyst Pharmaceuticals is currently valued in line with its profitable ...

Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) is the focus of IBN's latest stock spotlight. The company's shares have moved 2.49% on the day to $17.69. Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people w...